COST-EFFECTIVENESS OF INTERFERON-FREE THERAPY FOR HEPATITIS C IN GERMANY - AN APPLICATION OF THE EFFICIENCY FRONTIER APPROACH

被引：0
|
作者：
Gissel, C. [1 ,2 ]
Goetz, G. [1 ]
Mahlich, J. [3 ]
Repp, H. [2 ]
机构：
[1] Univ Giessen, Econ Ind Org Regulat & Antitrust 1, D-35390 Giessen, Germany
[2] Univ Giessen, Gen Med, D-35390 Giessen, Germany
[3] Janssen Cilag GmbH, Neuss, Germany
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30921-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0718
引用
收藏
页码：S593 / S593
页数：1
相关论文
共 50 条
  • [41] Pharmaceuticals Interferon-free therapy for hep C
    Dorey, Emma
    CHEMISTRY & INDUSTRY, 2012, 76 (11) : 15 - 15
  • [42] Interferon-Free Regimens for Hepatitis C: Combine and Conquer
    Valérie Martel-Laferrière
    Kian Bichoupan
    Douglas T. Dieterich
    BioDrugs, 2014, 28 : 161 - 169
  • [43] Interferon-Free Regimen for Hepatitis C: Insight and Management
    Masoud, Muhammad Shareef
    Ashfaq, Usman Ali
    Khalid, Hina
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2018, 28 (04): : 373 - 384
  • [44] Interferon-Free Regimens for Hepatitis C: Combine and Conquer
    Martel-Laferriere, Valerie
    Bichoupan, Kian
    Dieterich, Douglas T.
    BIODRUGS, 2014, 28 (02) : 161 - 169
  • [45] The role of genotyping in cost-effectiveness of interferon and ribavirin for chronic hepatitis C
    Younossi, ZM
    Singer, ME
    Shermock, KM
    McHutchison, JG
    GASTROENTEROLOGY, 1999, 116 (04) : A1293 - A1293
  • [46] COST-EFFECTIVENESS AND BUDGET IMPACT OF INTERFERON-FREE DIRECT-ACTING ANTIVIRAL (DAA)-BASED REGIMENS FOR CHRONIC HEPATITIS C TREATMENT. THE FRENCH CASE
    Deuffic-Burban, S.
    Obach, D.
    Canva, V.
    Pol, S.
    Roudot-Thoraval, F.
    Dhumeaux, D.
    Mathurin, P.
    Yazdanpanah, Y.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S470 - S471
  • [47] Characteristics of patients and effectiveness of chronic hepatitis C treatment during the initial 4 years of access to interferon-free therapy
    Flisiak, Robert
    Lorenc, Beata
    Jakub, Klapaczynski
    Janczewska, Ewa
    Mazur, Wlodzimierz
    Zarebska-Michaluk, Dorota
    Tudrujek, Magdalena
    Tomasiewicz, Krzysztof
    Dybowska, Dorota
    Halota, Waldemar
    Sitko, Marek
    Orlowska, Iwona
    Krzysztof, Simon
    Czauz-Andrzejuk, Agnieszka
    Belica-Wdowik, Teresa
    Berak, Hanna
    Jaroszewicz, Jerzy
    Krygier, Rafal
    Anna, Piekarska
    Socha, Lukasz
    Citko, Jolanta
    Beata, Dobracka
    Olga, Tronina
    Zbigniew, Deron
    Laurans, Lukasz
    Bialkowska-Warzecha, Jolanta
    Pawlowska, Malgorzata
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E222 - E223
  • [48] The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy
    Visentini, Marcella
    Colantuono, Stefania
    Granata, Guido
    de Santis, Adriano
    Fiorilli, Massimo
    Casato, Milvia
    HEPATOLOGY, 2015, 62 (03) : 975 - 975
  • [49] Interferon-Based and Interferon-Free Regimens for Patients With Chronic Hepatitis C, Genotype 1: Potential Cost-Effectiveness of Biopsy-Guided Treatment Versus Treat All Strategies
    Younossi, Zobair M.
    Singer, Mendel E.
    Mir, Heshaam M.
    GASTROENTEROLOGY, 2013, 144 (05) : S988 - S988
  • [50] Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C
    Grushko, Irina P.
    Romanova, Elena B.
    Tverdokhlebova, Tatiana I.
    Gapon, Marina N.
    Vodyanitskaya, Svetlana Yu.
    TERAPEVTICHESKII ARKHIV, 2022, 94 (08) : 979 - 984
12345